雷帕霉素联合ZD55-TRAIL病毒对肿瘤抑制及其机制探讨  

The Experimental Study on Cytotoxic Effect of Oncolytic Virus ZD55-TRAIL Combined With Rapamycin against Human Cancer Cells and the Exploration Mechanism

作　　者：刘锡君[1] 李新[1] 郑水娣[1] 钟丹[1] 章康健[2] 王世兵[1] 周秀梅[1] 

机构地区：[1]浙江理工大学生命科学学院新元医学与生物技术研究所,杭州310018 [2]中国科学院上海生命科学研究院生物化学与细胞生物学研究所,上海200031

出　　处：《中国细胞生物学学报》2011年第6期688-691,共4页Chinese Journal of Cell Biology

基　　金：浙江理工大学科研启动基金(No.0916819-Y)资助项目~~

摘　　要：溶瘤腺病毒的肿瘤靶向性研究一直是一个热点。目前已有商业化的ONYX-015、H101溶瘤腺病毒。在此基础上，科学家又进一步发展形成基因一病毒治疗方案，如文中应用的ZD55-TRAIL病毒。本研究利用刘新垣实验室提供的携带TRAIL（TNF-related apoptosis-inducing ligand，TNF相关的凋亡诱导配体）的溶瘤腺病毒ZD55-TRAILt^[1]联合雷帕霉素杀伤肿瘤细胞。ZD55-TRAIL是删除了腺病毒E1B-55KD，This research investigates the effect of combined application of oncolytic virus ZD55-TRAIL and the chemotherapeutic drugs Rapamycin （Rap） in growth inhibiton of human cancer cells in vitro. The effects of the treatment were measured by MTT assay and the replication of E1B-55KD deletion adenovirus was detected by the expression of E1A protein by Western blot. These observations suggest that Rapamycin could increase the levels of E1A, which may explain its ablitiy to enhance ZD55-TRAIL virus oncolysis. The combination therapy with signaling inhibitors that modulate activity of mTOR pathway will promote the cytotoxity against human cancer cells.

关 键 词：溶瘤腺病毒 雷帕霉素 肿瘤坏死因子相关的凋亡诱导配体 E4orf1 

分 类 号：R96[医药卫生—药理学]